StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)

Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –

ImmuCell price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ImmuCell's price to sales ratio was 3.0× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 1.6× to 3.9×, with a median of 2.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.0×+1.0
2025Dec 31, 20252.0×−0.4
2024Dec 31, 20242.4×+0.0
2023Dec 29, 20232.4×+0.1
2022Dec 30, 20222.4×−1.2
2021Dec 31, 20213.5×+0.7
2020Dec 31, 20202.8×−0.0
2019Dec 31, 20192.9×−0.6
2018Dec 31, 20183.5×−1.2
2017Dec 29, 20174.7×+2.4
2016Dec 30, 20162.3×−0.1
2015Dec 31, 20152.4×+0.3
2014Dec 31, 20142.1×−0.1
2013Dec 31, 20132.2×−0.1
2012Dec 31, 20122.3×−0.5
2011Dec 30, 20112.8×+0.7
2010Dec 31, 20102.1×–

More ImmuCell figures

See a number that looks wrong?